Dermtech Inc (DMTK) - News Archive

In a recent press release, DermTech, a prominent player in precision dermatology leveraging non-invasive skin genomics technology, announced that its special committee of board directors has engaged TD Cowen to explore...

SAN DIEGO - DermTech, a trailblazer in precision dermatology, revealed today its plans to delve into strategic alternatives to increase stockholder value. The special committee of the company s board of directors has en...

DermTech, a pioneering company in precision dermatology leveraging non-invasive skin genomics technology, has recently revealed its plans to implement additional restructuring measures. The is to prioritize revenue grow...

DermTech, Inc. (NASDAQ: DMTK), a leading provider of precision dermatology solutions powered by non-invasive skin genomics technology, recently announced positive topline results from two studies evaluating the DermTech...

DermTech, a pioneering company in precision dermatology, has announced a significant development in their DermTech Melanoma Test (DMT). Effective March 1, 2024, the optional TERT promoter mutation add-on assay will be d...

DermTech, a leading player in precision dermatology leveraging non-invasive skin genomics technology, has recently shared promising results from its Trust 2 Study. This study evaluated the foundational gene expression a...

DermTech, a leader in precision dermatology, has recently announced the issuance of restricted stock units to 15 new employees. This move falls under Nasdaq Listing Rule 5635(c)(4) and is in line with the company s 2022...